Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Gaithersburg, MD, 28 September 2016 - MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces that it granted options over a total of 140,000 shares of its common stock ("Common Stock") to certain employees of the Company ("Option Grants"). None of the Option Grants were provided to Directors or Persons Discharging Management Responsibilities ("PDMRs").

The Option Grants vest ratably on a monthly basis following grant, generally over 48 months.  The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire.  All the grants are effective of today, at an exercise price of 85.0p per option.

For further information please contact:

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/